Edition:
United States

Redhill Biopharma Ltd (RDHL.OQ)

RDHL.OQ on NASDAQ Stock Exchange Global Market

7.00USD
11 Dec 2018
Change (% chg)

-- (--)
Prev Close
$7.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
37,186
52-wk High
$11.47
52-wk Low
$4.41

Chart for

About

No overview information found for .
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  RDHL.OQ Industry Sector
P/E (TTM): -- 95.96 30.88
EPS (TTM): -- -- --
ROI: -- 0.60 13.80
ROE: -- -2.18 15.29

RedHill Biopharma's antibiotic succeeds in late-stage study

Israel-based RedHill Biopharma Ltd said on Monday its combination antibiotic met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine.

Dec 03 2018

UPDATE 1-RedHill Biopharma's antibiotic succeeds in late-stage study

Dec 3 Israel-based RedHill Biopharma Ltd said on Monday its combination antibiotic met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine.

Dec 03 2018

RedHill Biopharma's antibiotic succeeds in late-stage study

Dec 3 Israel-based RedHill Biopharma Ltd said on Monday its combination antibiotic met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine.

Dec 03 2018

RedHill BioPharma has positive results from Crohn's disease trial

TEL AVIV Israel's RedHill Biopharma said on Monday it had positive safety and efficacy results from a late-stage clinical trial with its treatment for Crohn's disease called RHB-104.

Jul 30 2018

RedHill BioPharma has positive results from Crohn's disease trial

TEL AVIV, July 30 Israel's RedHill Biopharma said on Monday it had positive safety and efficacy results from a late-stage clinical trial with its treatment for Crohn's disease called RHB-104.

Jul 30 2018

Earnings vs. Estimates

No consensus analysis data available.